Delivery Order SPE2DB22D2206-SPE2DB25FJX33
- Not listed
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $26,285.93 by the Defense Logistics Agency on July 18, 2025, for the supply of Ultomiris 300 mg/3 ml vials. This competitively awarded, firm fixed-price contract has no set-aside designation and is scheduled for completion by August 8, 2025. The award represents a child delivery order under AmerisourceBergen's broader relationship with the DLA, leveraging the company's established...
- The Defense Logistics Agency awarded a $9,558.52 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Ultomiris 300 mg/3 ml vials. This non-competitive delivery order, with an ultimate completion date of September 29, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- AmerisourceBergen Drug Corp, a leading pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $41,420.20 for Ultomiris 300 mg/3 ml vials on September 2, 2025, with an ultimate completion date of September 23, 2025. This firm fixed price, competitively awarded contract (No. 4569318413) is being funded by the Defense Logistics Agency's Medical Supply Chain, a Defense Department entity responsible for pharmaceutical and medical supply...
- The Defense Logistics Agency awarded a $50,978.64 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ultomiris (pegcetacoplan) 1,100 mg/11 ml vials. The award was made on September 11, 2025, with an ultimate completion date of October 2, 2025, and the product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a continuation of the company's...
- The Defense Logistics Agency awarded a $131,429.25 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ultomiris (pegcetacoplan) 1,100 mg/11 mL vials. This contract, issued on August 15, 2025, with an ultimate completion date of September 8, 2025, represents a non-set-aside competitive award supporting federal pharmaceutical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The Defense Logistics Agency awarded a $26,285.93 delivery order to AmerisourceBergen Drug Corp for the supply of Ultomiris (pegcetacoplan) 300 mg/3 mL vials on July 30, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed price contract contains no set-aside designation and identifies AmerisourceBergen's Conshohocken, Pennsylvania facility as the place of performance. The delivery order is a child contract under AmerisourceBergen's larger...
- This is a delivery order awarded by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $93,538.86 firm fixed-price contract is for the supply of 1,100 mg/11 ml vials of the specialty medication Ultomiris. The order is placed against AmerisourceBergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $106,187.70 firm fixed-price contract is for the supply of ULTOMIRIS 1,100 MG/11 ML VIAL 11ML, a specialty pharmaceutical product. The contract has an ultimate completion date of February 18, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of ULTOMIRIS 300 MG/3 ML VIAL 3ML medication. The single-award delivery order contract has a total ceiling value of $42,558.50 and a period of performance through May 29, 2024. The contract is a firm fixed-price arrangement with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp is a major pharmaceutical distributor that serves as a key...
- This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ultomiris 300 mg/3 ml vials. The contract has a firm fixed price of $51,070.20 and a completion date of July 26, 2024. It is not designated as a set-aside contract. The contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJX33Delivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a firm fixed-price delivery order valued at $23,896.30 by the Defense Logistics Agency (DLA) for the supply of Ultomiris 300 mg/3 ml vials. The contract, awarded on September 12, 2025, carries an ultimate completion date of October 3, 2025, and represents a non-set-aside competitive award. As a child order under a larger contract vehicle, this delivery order fulfills DLA's medical supply procurement requirements in support of military healthcare operations. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor and healthcare solutions provider for federal medical procurement, with an extensive portfolio of contracts through DLA Troop Support Medical. The company holds a significant Indefinite Delivery Contract (IDC) designated SPE2DX with a ceiling value of $999,999,999.00 running through December 2026, which serves as the overarching vehicle supporting multiple therapeutic domains including specialty medications, vaccines, and medical supplies for military healthcare systems worldwide. This delivery order for Ultomiris, a specialized pharmaceutical product, exemplifies the company's role in supplying critical brand-name medications through the DLA's competitive procurement process to support Defense Department healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.9k | 9/12/25 |